In response to the soaring increase in the cases of multi-drug resistant bacteria all over the world, we have tried an attempt to design a unique therapeutic formulation of antibiotic with an emphasis to increase the efficiency of antibiotic for the treatment of infections causes by MDR bacteria. We utilized gold nanoparticles (GNPs) as a drug carrier onto which various antibiotics are capped using our self-patented single step ecofriendly process to yield antibiotic capped gold nanoparticles (Ab-GNPs). For this study, a range of frontline antibiotics were chosen like kanamycin, ceftazidime and gentamicin which have shown a decrease in their potency due to development of resistance in bacteria. Synthesized Ab-GNPs were morphologically characterized using various analytical techniques such as TEM, SEM-EDS and UV-Vis spectroscopy. The presence of organic content was determined using TGA, DSC and DLS analysis. Antibacterial activity of antibiotic-GNPs was evaluated using various in-vitro assays including bacterial growth, spread plate and colorimetric assay against both Gram-positive and Gram-negative bacterial strains to obtain the minimum inhibitory concentration (MIC) which was compared with the respective pure antibiotic. The antibacterial aspects of antibiotic-GNPs along with drug delivery capabilities is used to develop an innovative and novel drug platform to increase the efficacy of FDA approved antibiotics, and slow the development of antibiotic resistance in susceptible strains.

Antibiotic in disguise for treating multidrug resistant bacteria

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.